H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Celldex (CLDX) to $50 from $80 and keeps a Buy rating on the shares following the Q1 report. The firm expects 2025 to be a year of continued execution across the company’s pipeline, and highlight the current status of the ongoing programs.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex’s Promising Pipeline and Strong Financial Position Justify Buy Rating
- Celldex reports Q1 EPS (81c), consensus (74c)
- Optimistic Buy Rating for Celldex Driven by Promising Barzolvolimab Developments and Strong Financial Position
- Promising Phase 2 Results for Celldex’s Barzolvolimab in Eosinophilic Esophagitis Boosts Buy Rating
- Celldex presents histology data from barzolvolimab study